GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
A
A
Fasan
C
C
Eder
C
C
Haferlach
V
V
Grossmann
A
A
Kohlmann
F
F
Dicker
W
W
Kern
T
T
Haferlach
S
S
Schnittger
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics*; D005260:Female; D050989:GATA2 Transcription Factor / Q000235:genetics*; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D055815:Young Adult
D022762:CCAAT-Enhancer-Binding Proteins; C515848:CEBPA protein, human; D050989:GATA2 Transcription Factor; C494711:GATA2 protein, human; D012333:RNA, Messenger